Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 8.03% is in line with its 1-year average of 7.92%, around the middle of its 1-year range (1.84%–11.62%).
20.78% above its 12-month average of 6.65%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 7.22%.
EBITDA MARGIN
8.03%
EBITDA MARGIN AVG TTM
6.65%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+20.78%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.02B
EBITDA Margin
8.03%
TTM Avg
6.65%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
EBITDA Margin
-1556.38%
TTM Avg
-1235.25%
3Y Avg
-1029.62%
5Y Avg
-1004.15%
Market Cap
$1.01B
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$1.03B
EBITDA Margin
13.41%
TTM Avg
11.95%
3Y Avg
15.57%
5Y Avg
17.13%
Market Cap
$1.04B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$1.04B
EBITDA Margin
-0.59%
TTM Avg
3.42%
3Y Avg
-15.99%
5Y Avg
-18.77%
Market Cap
$993.25M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$983.98M
EBITDA Margin
-114.71%
TTM Avg
-284.80%
3Y Avg
-531.58%
5Y Avg
-445.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.02B | 8.03% | 6.65% | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -1556.38% | -1235.25% | -1029.62% | -1004.15% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -358.45% | -358.45% | -358.45% | -358.45% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 13.41% | 11.95% | 15.57% | 17.13% |
| Immatics N.V. (IMTX)vs › | $1.04B | -351.42% | -184.18% | -130.50% | -161.84% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -0.59% | 3.42% | -15.99% | -18.77% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $993.25M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| MeiraGTx Holdings plc (MGTX)vs › | $983.98M | -114.71% | -284.80% | -531.58% | -445.59% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $983.52M | -31.64% | -36.17% | -63.38% | -163.90% |
Gross Margin
11.8%
EBITDA Margin
8.0%
Operating Margin
1.4%
Net Margin
-2.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 7.22% |
| 2026-03-31 | 7.35% |
| 2025-12-31 | 1.84% |
| 2025-09-30 | 10.18% |
| 2025-03-31 | 9.33% |
| 2024-12-31 | 11.62% |
